secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2026-05-12T20:07:19+00:00
Accession:  0001193125-26-219395
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q1 2026: Net revenue $5.0M; YCANTH units up 51% YoY; net loss $9.7M
---------------------------------------------------------------------------

- YCANTH dispensed units 15,302 (+12.1% QoQ, +51.3% YoY); net product revenue $4.3M (+16.2% QoQ, +25.4% YoY).
- Total revenue $5.0M includes $0.7M license/collaboration revenue from Torii Japan launch.
- Net loss $9.7M ($0.45 per share); non-GAAP net loss $8.8M ($0.41 per share).
- Phase 3 common warts trial (COVE-2) >50% enrolled; second trial (COVE-3) expected mid-2026.
- Appointed Chris Chapman as Chief Commercial Officer; Phase 2 VP-315 BCC data to be presented at SID May 13-16.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/0001193125-26-219395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer